Intact Therapeutics
YC W19San Francisco, US · Founded 2015 · 4 employees · 2 known investors
Intact Therapeutics develops next-generation biopharmaceutical therapies for gastrointestinal diseases to address unmet clinical needs. The company is clinical-stage and focused on improving patient outcomes through innovative medicines.
Founders & leadership· Y Combinator alumni (W19)
Intact Therapeutics was founded in 2015 by Ravi Pamnani and Sidhartha Sinha.
RP
Ravi PamnaniinCEO & Co-FounderFounder and CEO of Intact Therapeutics, a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases.
SS
Sidhartha SinhainFounder
Investors · 2
Competitors · 4
by search overlapIntracellular Therapies5 shared keywordsIntra-Cellular Therapies develops treatments for neuropsychiatric, neurologic, and related disorders, including its product CAPLYTA. The company is now part of Johnson & Johnson.
Iteriontherapeutics3 shared keywordsIterion Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies targeting the Wnt/β-catenin pathway. Its lead candidate is in clinical trials for advanced hepatocellular carcinoma and other Wnt-driven tumors such as colorectal cancer.
Entactbio3 shared keywordsEntact is a drug discovery company developing treatments for patients. It works in the biotechnology and therapeutics sector.
Incyte Corporation3 shared keywordsIncyte is a global biopharmaceutical company that develops medicines across hematology, oncology, and inflammation and autoimmunity, with clinical programs spanning areas such as dermatology. It focuses on research and development of treatments for patients.
Companies competing with Intact Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $296.5K |
| National Science Foundation | Phase I | 2020 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Intact Therapeutics do?
- Intact Therapeutics develops next-generation biopharmaceutical therapies for gastrointestinal diseases to address unmet clinical needs. The company is clinical-stage and focused on improving patient outcomes through innovative medicines.
- Who founded Intact Therapeutics?
- Intact Therapeutics was founded by Ravi Pamnani, Sidhartha Sinha in 2015.
- Who are Intact Therapeutics's investors?
- Intact Therapeutics's investors include Brightstone Venture Capital, Y Combinator.
- Where is Intact Therapeutics headquartered?
- Intact Therapeutics is headquartered in San Francisco, US.